To listen to the interview, recorded live via Uberconference, click on the following video (41:37 min). A transcript of the interview is also available below.
3 min read
7 min read
As states begin to loosen restrictions and we try and put COVID-19 in the rear view mirror, in the words of Bill Gates, "it's going to be a while before we can get back to normal" and companies are going to have to find creative ways to stay connected and engaged while moving forward and getting work done.
The following is a small sampling of Regenerative Medicine segment updates from the past week that were compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present news, analysis, studies, trial results, patents and financial data that are most relevant to our subscribers.
For 2020, the TOBI Conference was held virtually due to COVID-19; still, attendance was fairly high. During one of the Virtual Lounge Q&A discussions, it appears that there is an emerging trend w/ some practitioners doing PRP inj then HA inj, not the other way around for knee.
BOTHE informed that in EU several clinical sites for JTA-004 Phase III trial have resumed recruitment as COVID-19 lockdown measures are lifted; 34 pts have been treated since the initiation of the trial mid-May 2020. Reporting of the topline results is currently planned for H221.
This study presents a detachable hybrid microneedle depot (d‐HMND) for cell delivery The system deploys an array of "microneedles" w/ MSCs embedded in a gel-like matl, which prolongs cell viability & functionality, penetrating into a target tissue w/ high spatial precision. ADFM
US Patent Application “PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF” was published, relating to compositions for PRP depleted in neutrophils to treat damaged connective tissue &/or slow/stop cardiac apoptosis after a heart attack, along w/ reperfusion therapy. 20200179455
3 min read
Location: Northeast US near the Boston Area
Are you a proven hunter with a successful track record in medical device or healthcare enterprise sales? Are you looking for flexibility beyond your four office walls? Would you thrive in an entrepreneurial environment? If so, we’d like to talk to you. We’re BioMedGPS the creators of SmartTRAK, the leading strategic advisory and healthcare analytics provider in the life sciences industry. Our team is expanding and seeking a Enterprise Sales Executive who can grow with us. The Enterprise Sales Executive will be responsible for selling SmartTRAK’s suite of business intelligence solutions to C- suite and other senior level executives in major medical device companies, as well as building long term strategic programs and relationships at all levels of the enterprise.
SmartTRAK is the first real-time business intelligence portal used by major orthopedic, wound, regenerative medicine and neuro therapies companies. We are driven by data but fueled by insights. Curated by industry experts, our up-to-date data, analytics and competitive intelligence help medical device executives make more informed strategic business decisions.
12 min read
The GID Group – Prepping to revolutionize Regenerative Medicine with an innovative modular tissue processing platform
In December, at IFATS 2019, William “Bill” Cimino, PhD, CEO of The GID Group (GID) sat down with SmartTRAK to discuss the Company’s novel modular tissue processing platform, which reduces an entire GMP cell-processing facility to a single disposable device, enabling physicians to extract and process adipose tissue in real time for use in a wide range of applications.
GID is a privately held, clinical stage cellular medicine company currently working on developing a tissue processing platform, the GID SVF-2 device, that enables cell-based treatments.
To find out more about the GID Group, its revolutionary technology and product candidate, click on the following video to listen to SmarTRAK’s interview with Bill Cimino, recorded live at the IFATS Annual Meeting held in Marseille, France December 3-7, 2019. A transcript of the interview is also provided below.
8 min read
4 min read
4 min read
OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.
Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.
What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?
To have a presence in the entire US HA market, OrthogenRx aims to provide...
2 min read
Frederique Buntoum (aka Freddy), SmartTRAK's Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules, will be representing SmartTRAK at TOBI 2019, the Tenth Annual PRP & Regenerative Medicine Symposium in Chicago, IL, June 6-8.
You can view Freddy's intro video below...
1 min read
Frederique Buntoum (aka Freddy) has joined BioMedGPS as Senior Analyst, Regenerative Medicine, overseeing the Cell Processing, Amniotic Tissue and Joint Fluid modules. Formerly Senior Manager of Market Insights at Bioventus, Freddy has broad experience in sales, marketing and competitive intelligence. Her passion for market research and uncovering the “why” behind industry developments complements SmartTRAK’s team of domain experts and her thoughtful and keen insights and out-of-the-box perspective on market happenings make her a great addition to the SmartTRAK analyst team.
In addition to her role as an analyst, Freddy will also be assisting with consulting projects and product development initiatives – two key areas that will contribute to BioMedGPS growth in 2019.
Freddy will be representing SmartTRAK at the upcoming AAOS meeting. Please Contact us if you would like to set up a time to meet.
3 min read
According to BioMedGPS’ SmartTRAK Financial Dashboard, in Q318, the US Surgical Matrices Market grew +10.3% YoY. The allograft breast matrices and biosynthetic hernia matrices segments outpaced overall market growth, as both posted...
Among the many interesting topics covered in the Q318 US Surgical Matrices Market Recap are: